TrialSignal
Clinical trial intelligence report
Dose Response Study of AMG 162 (Denosumab) in Subjects With Osteoporosis - A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects -
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT00306189
Status
COMPLETED
Phase
PHASE2
Sponsor
Amgen
Executive brief
Investment-Ready Snapshot
The primary objective of this study is to assess the effect of AMG 162 (denosumab) treatment on the lumbar spine BMD at month 12 and safety profile across the dose range tested (14, 60 and 100 mg SC once every 6 months) in Japanese postmenopausal osteoporotic subjects compared with those treated with placebo over 12 months.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00306189
Indication
Osteoporosis
Modality
monoclonal antibody
Target
100 mg AMG 162, 60 mg AMG 162, 14 mg AMG 162, Placebo
Intervention
100 mg AMG 162, 60 mg AMG 162, 14 mg AMG 162, Placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.